Edwards Lifesciences had five patents in future of work during Q4 2023. The patent filed by Edwards Lifesciences Corp in Q4 2023 involves a process for monitoring heart valve function by placing transducers on a patient’s body to receive signals indicating blood flow velocity profiles associated with the heart. The severity of dysfunction in a heart valve is determined based on the identified peaks in the blood flow velocity profile. GlobalData’s report on Edwards Lifesciences gives a 360-degreee view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Edwards Lifesciences Corp - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

Edwards Lifesciences grant share with future of work as a theme is 60% in Q4 2023. Grant share is based on the ratio of number of grants to total number of patents.

Recent Patents

Application: Heart valve dysfunction detection (Patent ID: US20230338001A1)

The patent filed by Edwards Lifesciences Corp. describes a method and system for monitoring heart valve function by placing transducers on a patient's body to receive signals indicating blood flow velocity profiles associated with the heart. The severity of dysfunction in a heart valve is determined based on identifying peaks in the blood flow velocity profiles, with the method allowing for differentiation between forward-flow and regurgitant-flow components to assess the dysfunction accurately. The system includes control circuitry to perform these functions and can determine whether the peak flow is associated with the mitral or aortic valve based on the direction of blood flow relative to the transducers.

Additionally, the patent details a method for calibrating the transducers by taking blood flow measurements using a handheld transducer before placement. The system can separate forward-flow and regurgitant-flow components by utilizing independent blood flow measurements from different transducers positioned at varying angles. The severity of dysfunction in the heart valves, such as aortic stenosis or mitral regurgitation, is determined based on the separated components of the blood flow peaks. Overall, the invention provides a comprehensive approach to monitoring heart valve function accurately and efficiently through the analysis of blood flow velocity profiles.

To know more about GlobalData’s detailed insights on Edwards Lifesciences, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.